tetano
Editor, Senior Moderator
J Gen Virol. 2016 Nov 2. doi: 10.1099/jgv.0.000651. [Epub ahead of print]
[h=1]Establishment of memory CD8+ T cells with live attenuated influenza virus (LAIV) across different vaccination doses.[/h] Wang Z[SUP]1[/SUP], Kedzierska L[SUP]2[/SUP], Nuessing S[SUP]3[/SUP], Chua B[SUP]4[/SUP], Qui?ones-Parra SM[SUP]5[/SUP], Huber VC[SUP]6[/SUP], Jackson D[SUP]7[/SUP], Thomas PG[SUP]8[/SUP], Kedzierska K[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] FluMist has been used in children and adults for more than ten years. As pre-existing CD8+ T-cell memory pools can provide heterologous immunity against distinct influenza viruses, it is important to understand influenza-specific CD8+ T-cell responses elicited by different LAIV regimens. In this study, we immunized mice intranasally (i.n.) with two different doses of live-attenuated PR8 virus (PR8 ts, H1N1), low and high, and then assessed protective efficacy by challenging animals with heterosubtypic X31-H3N2 virus at 6 weeks post-vaccination. Different LAIV doses elicited influenza-specific CD8+ T-cell responses in lungs and spleen, but unexpectedly not in brochoalveolar lavage (BAL). Interestingly, the immunodominance hierarchy at the acute phase after immunization varied depending on the LAIV dose, however these differences disappeared at 6 weeks post-vaccination, resulting in generation of comparable CD8+ T-cell memory pools. After vaccination with either dose, sufficient numbers of specific CD8+ T-cells were generated for recall and protection of mice against heterosubtypic H1N1->H3N2 challenge. As a result, immunized mice displayed reduced weight loss, diminished inflammatory responses and lower viral titres in lungs, when compared to unvaccinated animals. Interestingly, the higher dose led to enhanced viral clearance on day 5 post-challenge, though this was not associated with increased CD8+ T-cell responses, but with higher levels of non-neutralizing antibodies against the priming virus. Our study suggests that while different LAIV doses result in distinct immune profiles, even a low dose produces sufficient protective CD8+ T-cell memory against challenge infection, though the high dose results in more rapid viral clearance and reduced inflammation.
PMID: 27902386 DOI: 10.1099/jgv.0.000651
[PubMed - as supplied by publisher]
[h=1]Establishment of memory CD8+ T cells with live attenuated influenza virus (LAIV) across different vaccination doses.[/h] Wang Z[SUP]1[/SUP], Kedzierska L[SUP]2[/SUP], Nuessing S[SUP]3[/SUP], Chua B[SUP]4[/SUP], Qui?ones-Parra SM[SUP]5[/SUP], Huber VC[SUP]6[/SUP], Jackson D[SUP]7[/SUP], Thomas PG[SUP]8[/SUP], Kedzierska K[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] FluMist has been used in children and adults for more than ten years. As pre-existing CD8+ T-cell memory pools can provide heterologous immunity against distinct influenza viruses, it is important to understand influenza-specific CD8+ T-cell responses elicited by different LAIV regimens. In this study, we immunized mice intranasally (i.n.) with two different doses of live-attenuated PR8 virus (PR8 ts, H1N1), low and high, and then assessed protective efficacy by challenging animals with heterosubtypic X31-H3N2 virus at 6 weeks post-vaccination. Different LAIV doses elicited influenza-specific CD8+ T-cell responses in lungs and spleen, but unexpectedly not in brochoalveolar lavage (BAL). Interestingly, the immunodominance hierarchy at the acute phase after immunization varied depending on the LAIV dose, however these differences disappeared at 6 weeks post-vaccination, resulting in generation of comparable CD8+ T-cell memory pools. After vaccination with either dose, sufficient numbers of specific CD8+ T-cells were generated for recall and protection of mice against heterosubtypic H1N1->H3N2 challenge. As a result, immunized mice displayed reduced weight loss, diminished inflammatory responses and lower viral titres in lungs, when compared to unvaccinated animals. Interestingly, the higher dose led to enhanced viral clearance on day 5 post-challenge, though this was not associated with increased CD8+ T-cell responses, but with higher levels of non-neutralizing antibodies against the priming virus. Our study suggests that while different LAIV doses result in distinct immune profiles, even a low dose produces sufficient protective CD8+ T-cell memory against challenge infection, though the high dose results in more rapid viral clearance and reduced inflammation.
PMID: 27902386 DOI: 10.1099/jgv.0.000651
[PubMed - as supplied by publisher]